<DOC>
	<DOCNO>NCT02965885</DOCNO>
	<brief_summary>A First-in-Human ( FIH ) study TAS-116 patient advance solid tumor first initiate Japan April 2014 ongoing since . The study consist dose escalation phase dose expansion phase . Three dose regimen TAS-116 , daily ( QD ) , every day ( QOD ) 5 day on/2 day regimens 21-day cycle , evaluate . This phase I study also plan enrol advance solid tumor UK confirm MTD , safety , tolerability , pharmacokinetics TAS-116 Western patient population dose expansion phase . In addition , patient HER2+ MBC , NSCLC harbour EGFR mutation ( EGFRT790M+ ) EGFR mutation ( T790M- ) evaluate safety , tolerability efficacy 3 separate cohort recommend dose TAS-116 5 day on/2 day regimen .</brief_summary>
	<brief_title>A Study TAS-116 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Male female age ≥ 18 year ( ≥ 20 year Japan ) 2 . Patients histological cytologicalconfirmed , advance unresectable breast , gastric , nonsmall cell lung cancer , progress ( able tolerate ) standard therapy standard anticancer therapy exist . . Part C : Only follow subtype tumor molecular/genetic alteration enrol : HER2 positive MBC Advanced NSCLC , EGFR T790M positive Advanced NSCLC , EGFR T790M negative 3 . At least one measurable lesion solid tumor . 4 . Is able take medication orally ( e.g. , feed tube ) . 5 . Able agree sign inform consent comply protocol 6 . Has adequate organ function 1 . Has serious illness medical condition ( ) 2 . Has receive treatment proscribed treatment within specified time frame prior study drug administration 3 . Significant ophthalmologic abnormality , 4 . Impaired cardiac function clinically significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>MTD</keyword>
	<keyword>TAS116</keyword>
	<keyword>HSP90 Inhibitor</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>HER2 positive MBC</keyword>
	<keyword>NSCLC EGFR T790M Positive</keyword>
	<keyword>NSCLC EGFR T790M Negative</keyword>
</DOC>